

Zhen-Man Lin
c/o Anthonng Yim
54 Heather Road
Meltham Holmfirth
HUDDERSFIELD
HD9 4HT

**The Patent Office
Patents Directorate**

Concept House
Cardiff Road, Newport
South Wales, NP10 8QQ

Examiner: 01633 814531
E-Mail: bill.thomson@patent.gov.uk
Switchboard: 01633 814000
Fax: 01633 814444
Minicom: 08459 222250
DX: 722540/41 Cleppa Park 3
http://www.patent.gov.uk

Your Reference: -
Application No: GB0318315.9

7 February 2007

Dear Sirs

Patents Act 1977: Examination Report under Section 18(3)

Title: Surface Treatment of SARS-Infected Lungs

Latest date for reply:

7 June 2007

I have examined your application and I am of the opinion that it does not comply with the requirements of the Patents Act. My enclosed report explains why.

Opportunity to file amendments

By the above date you should deal with the points raised in the report by filing amendments. These should be in the form of retyped pages filed in duplicate. However if you do not agree with the report, then you should explain your reasons in a letter.

No additional technical information allowed

When you reply, you should avoid giving any additional technical information about the invention (such as a modification) either by way of amendment or in an accompanying letter, as this would prevent you from subsequently obtaining a patent based on this information.

Further action

If after receiving your reply there are still points which need attention, I will contact you again. Should we still disagree, then the matter can be referred to a senior officer who will consider the issues afresh. You would have the opportunity, in this event, to come to the Office and present your opinion personally.



or Innovation

Application No : GB0318315.9

Page 2

7 February 2007

Further information

The Patent Office has produced two explanatory booklets (**patents: essential reading and patents: application guide**) which provide important information about the patent system. If you do not have these booklets already, please contact our Central Enquiry Unit on 08459 500505 to request copies.

Addressing correspondence

All correspondence should be addressed to the Comptroller.

While my e-mail address is provided above, you should note that the Office is unable to accept documents, such as amendments to the specification, transmitted by e-mail. Your official response to my report must therefore be delivered by post, fax or hand. However, you may use e-mail if you have any questions about the report or the processing of the application.

Consequence of failing to reply

The application may be refused unless you reply to this report by the date set.

Use of a patent agent

Your interests may be best served by employing a patent agent to act for you in pursuing your application

Yours faithfully

Dr Bill Thomson
Examiner

Your ref :	-	Examiner :	Dr Bill Thomson	
Application No:	GB0318315.9	Tel :	01633 814531	
Applicant :	Zhen-Man Lin	Date of report :	7 February 2007	
Latest date for reply:	<table border="1"><tr><td>7 June 2007</td></tr></table>	7 June 2007	Page 1/2	
7 June 2007				

Patents Act 1977 Examination Report under Section 18(3)

Basis of the examination

1. My examination has taken account of the amendments filed with your letters of 12 December 2003, 27 December 2003 and 1 March 2004.

Clarity of claims

2. In my Search Report of 4/12/03, I informed you that since your application does not define your invention clearly I searched for a composition comprising ozone and a polyfluorocarbon (PFC) for use in the treatment of severe acute respiratory syndrome (SARS). Upon re-examination of your application, I believe that the following problems still exist;

Novelty – Section 2(1)/2(2)

3. Section 2(1) states effectively that an invention shall be taken to new if it does **not** form part of the state of the art. Section 2(2) states that an invention will form the state of the art if it has been made available to the public at any time before the priority date of that application, be it in written form, oral description, by use or by any other way.

4. Although your invention is not set out clearly, it seems that it is not new in view of what is disclosed in the following documents:

(a) “Surface treatment of SARS-infected lungs”, Zhen-Man Lin, 20th May 2003, www.ycec.com/Surface-Treatment-of-SARS-e200503.htm - See whole document.

(b) WPI Abstract Accession No 2002-721810/78 & RU 2187984 (G UCHREZH DENIE MEZHOTRASLEVOJTEKHN KOMPLEKS MIKROKHIRURGIJA) 27/08/2002 – See abstract.

5. Document (a) discloses your entire invention – i.e., the treatment of SARS using a composition comprising ozone and a polyfluorocarbon for pulmonary delivery. Document (b) discloses that compositions comprising ozone and a PFC *per se* are known in the prior art.

6. Your invention lacks novelty, primarily because of your prior disclosure to the WHO on May 20th 2003 and placement of document (a) on the internet before the priority date 12 June



For Innovation

Your ref : -
Application No : GB0318315.9

Date of report: 7 February 2007
Page 2 / 2

[Examination Report contd.]

2003. It should be noted that an internet search was made for any reference to document (a) – i.e., any discussion of it on the internet before the priority date – and the following internet address was found–

www.nearlyemptyrooms.com/2003_02_01_archive.shtml (copy enclosed)

The above document on the diary date of 24 May 2003 makes reference to :

www.ycec.com/SARS-to-die-e.htm

This shows without doubt that your paper on the use of ozone/PFC for pulmonary delivery was made available to the public before the priority date of 12 June 2003. Such disclosure is fatal to your current application.

Further, in light of your admission that you disclosed your invention to the WHO in Geneva before the priority date (May 20 2003), I have to recommend that you do not proceed any further with the current application as the subject matter already forms part of the prior art.

Other matters

7. I would like to suggest that in the future, any invention that you do come up with be filed at the Patent Office of your choice **before** you disclose the invention to any third party. Further, I would also recommend that you consult a Patent Attorney.

Obvious, I know, but it was very clearly illustrated today.

posted by [Gareth # 12:48 AM](#)

Saturday, May 24, 2003

Just got the following amusing spam. It's ages since I've done chemistry, but aren't unbonded oxygen atoms rather reactive, and wouldn't sticking them inside your lungs be rather messy...

Subject ☐F Announce to defeat SARS virus! Rewrite pneumonia disease medical history!

You can download by :

English: www.ycec.com/SARS-to-die-e.htm

HK, TW www.ycec.com/SARS-to-die.htm CN www.ycec.com/SARS-to-die-c.htm

After that share human civilized common victory, to set into actio your government sanitary department urgent to enginee to clinical practice, save person as same fire fighting!

Surface Treatment of SARS-Infected Lungs

The sterilizing liquid injected into lung lobes is the surface treatment liquid for O1 therapy of the lungs. The formal name for this liquid is Per fluoro chemicals (PFC) and the sterilizer is Ozone.

This method of introducing supersonic wave with sterilizing liquid may make SARS virus less adsorptive and quickly clear viruses in the lungs. This new and practical therapy works like bombing the SARS virus with smart cruise missiles. The missile is single oxygen (O1) separated from ozone, hence ☐gO1 Therapy ☐h!

posted by [Gareth # 12:10 PM](#)

Friday, May 23, 2003

I'm currently looking through the [League of Extraordinary Gentlemen](#) movie site. I love the comic, and like every other fan, am more than a little apprehensive about the movie. Some of the stuff on the site is badly written and amazingly clueless. Still, it all looks pretty.

posted by [Gareth # 8:25 PM](#)

[This may amuse.](#)

posted by [Gareth # 5:30 PM](#)

Thursday, May 22, 2003

Matrix Reloaded

I could post an awful lot of theorising (for example, did the movement-through-the-screens in the Architect's room imply that we're seeing different potential Neos? Did the Oracle program Trinity to